Evidence map›Paper›PMID 26674961›Full record

ArticleBMC gastroenterology2015

Decreased PCSK9 expression in human hepatocellular carcinoma.

Mamatha Bhat, Nicolas Skill, Victoria Marcus, Marc Deschenes, Xianming Tan, Jeanne Bouteaud, Sarita Negi, Zuhier Awan, Reid Aikin, Janet Kwan and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. The evolving landscape of PCSK9 inhibition in cancer.European journal of pharmacology · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Mamatha BhatDivision of Gastroenterology, McGill University Health Centre, 687 Pine Avenue West, Montreal, H3A1A1, Canada. mamatha.bhat@mcgill.ca.
Nicolas SkillDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. nskill@iupui.edu.
Victoria MarcusDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada. victoria.marcus@muhc.mcgill.ca.
Marc DeschenesDivision of Gastroenterology, McGill University Health Centre, 687 Pine Avenue West, Montreal, H3A1A1, Canada. marc.deschenes@muhc.mcgill.ca.
Xianming TanBiostatistics Core Facility, Research Institute, McGill University Health Centre, Montreal, QC, Canada. Xianming.tan@clinepi.mcgill.ca.
Jeanne BouteaudHepatopancreatobiliary and Multi-Organ Transplant Surgery, McGill University Health Centre, Montreal, QC, Canada. Jeanne.bouteaud@mail.mcgill.ca.
Sarita NegiHepatopancreatobiliary and Multi-Organ Transplant Surgery, McGill University Health Centre, Montreal, QC, Canada. sarita.negi@gmail.com.
Zuhier AwanDepartment of Medical Biochemistry, King Abdulaziz University, Jeddah, Saudi Arabia. zuhier.awan@gmail.com.
Reid AikinHepatopancreatobiliary and Multi-Organ Transplant Surgery, McGill University Health Centre, Montreal, QC, Canada. reidaikin@gmail.com.
Janet KwanHepatopancreatobiliary and Multi-Organ Transplant Surgery, McGill University Health Centre, Montreal, QC, Canada. janet.kwan@mail.mcgill.ca.
Ramila AmreDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. ramila.amre@muhc.mcgill.ca.
Sebastien TabariesDepartment of Medicine, Goodman Cancer Research Centre, Montreal, QC, Canada. sebastien.tabaries@mcgill.ca.
Mazen HassanainDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada. mazen.hassanain@mcgill.ca.
Nabil G SeidahDepartment of Medical Biochemistry, King Abdulaziz University, Jeddah, Saudi Arabia. nabil.seidah@ircm.qc.ca.
Mary MaluccioDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. mmalucci@iupui.edu.
Peter SiegelDepartment of Medicine, Goodman Cancer Research Centre, Montreal, QC, Canada. peter.siegel@mcgill.ca.
Peter MetrakosDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada. peter.metrakos@mcgill.ca.
McGill University Health Centre · CAIndiana University School of MedicineKing Abdulaziz University · SAOccupational Cancer Research Centre · CAIndiana University – Purdue University Indianapolis · USKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism.

methodsThirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA.

resultsBy immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value < 0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value <0.0001), and positivity (percentage of positive cells) was significantly greater in cirrhosis compared to HCC (p-value < 0.0001). Conversely, significantly higher expression of LDL-R was present in HCC as compared to the adjacent cirrhosis (p-value < 0.0001). There was no significant correlation of PCSK9 staining with grade of tumor, but there were significant correlations between PCSK9 staining and stage of fibrosis, according to spearman correlation test. PCSK9 mRNA levels were relatively less abundant within HCC compared to adjacent liver tissue (p-value =0.08) and normal control tissue (p-value =0.02). In contrast, serum PCSK9 levels were significantly increased among patients with HCC compared to those with chronic liver disease without HCC (p-value =0.029). LDL receptor mRNA was consistantly greater in HCC when compared to normal control tissue (p-value = 0.06) and, in general, was significantly greater in HCC when compared to adjacent liver (p-value = 0.04).

conclusionsThe decreased expression of PCSK9 and conversely increased LDL-R expression in HCC suggests that HCC modulates its local microenvironment to enable a constant energy supply. Larger-scale studies should be conducted to determine whether PCSK9 could be a therapeutic target for HCC.

Indexed as

Carcinoma, HepatocellularFemaleHumansImmunohistochemistryLiverLiver CirrhosisLiver NeoplasmsMaleMiddle AgedProprotein Convertase 9Proprotein ConvertasesReal-Time Polymerase Chain ReactionReceptors, LDLSerine EndopeptidasesStatistics, NonparametricPCSK9 protein, humanProprotein Convertase 9Proprotein ConvertasesReceptors, LDLSerine Endopeptidases

Identifiers

PMID26674961
PMCPMC4682218
OpenAlexW2215742785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.